

# Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs)

Antônio Talvane Torres de Oliveira · Céline Pinheiro · Adhemar Longatto-Filho · Maria Jose Brito · Olga Martinho · Delcio Matos · André Lopes Carvalho · Vinícius Lima Vazquez · Thiago Buosi Silva · Cristovam Scapulatempo · Sarhan Sydney Saad · Rui Manuel Reis · Fátima Baltazar

Received: 18 December 2011 / Accepted: 27 December 2011 / Published online: 27 January 2012  
© Springer Science+Business Media, LLC 2012

**Abstract** Monocarboxylate transporters (MCTs) have been described to play an important role in cancer, but to date there are no reports on the significance of MCT expression

in gastrointestinal stromal tumors (GISTs). The aim of the present work was to assess the value of MCT expression, as well as co-expression with the MCT chaperone CD147 in

---

Antônio Talvane Torres de Oliveira and Céline Pinheiro contributed equally to the study

---

A. T. T. de Oliveira · A. L. Carvalho · V. L. Vazquez · T. B. Silva · C. Scapulatempo  
Departments of Digestive Surgery and Pathology and Centre for Researcher Support, Barretos Cancer Hospital, Pio XII Foundation, Barretos, São Paulo, Brazil

A. T. T. de Oliveira  
e-mail: netto123@uol.com.br

A. L. Carvalho  
e-mail: alopescarvalho@uol.com.br

V. L. Vazquez  
e-mail: viniciusvazquez@gmail.com

T. B. Silva  
e-mail: thiagonap@hcancerbarretos.com.br

C. Scapulatempo  
e-mail: cristovamscapula@uol.com.br

C. Pinheiro · A. Longatto-Filho · O. Martinho · R. M. Reis · F. Baltazar (✉)  
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal  
e-mail: fbaltazar@ecsau.de.uminho.pt

C. Pinheiro  
e-mail: cpinheiro@ecsau.de.uminho.pt

A. Longatto-Filho  
e-mail: longatto16@hotmail.com

O. Martinho  
e-mail: olgamartinho@esaude.uminho.pt

R. M. Reis  
e-mail: rreis@ecsau.de.uminho.pt

C. Pinheiro · A. Longatto-Filho · O. Martinho · R. M. Reis · F. Baltazar  
ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal

A. Longatto-Filho  
Laboratory of Medical Investigation (LIM) 14, Department of Pathology, University of São Paulo School of Medicine, Sao Paulo, Brazil

M. J. Brito  
Department of Pathology, Hospital Garcia de Orta, Almada, Portugal  
e-mail: mbrito@hgo.min-saude.pt

D. Matos · S. S. Saad  
Department of Gastroenterology, Medical School of the Federal University of São Paulo (UNIFESP), Sao Paulo, Brazil

D. Matos  
e-mail: dmatos.dcir@epm.br

S. S. Saad  
e-mail: saadss.dcir@epm.br

R. M. Reis  
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil

GISTs and evaluate their clinical-pathological significance. We analyzed the immunohistochemical expression of MCT1, MCT2, MCT4 and CD147 in a series of 64 GISTs molecularly characterized for *KIT*, *PDGFRA* and *BRAF* mutations. MCT1, MCT2 and MCT4 were highly expressed in GISTs. CD147 expression was associated with mutated *KIT* ( $p=0.039$ ), as well as a progressive increase in Fletcher's Risk of Malignancy ( $p=0.020$ ). Importantly, co-expression of MCT1 with CD147 was associated with low patient's overall survival ( $p=0.037$ ). These findings suggest that co-expression of MCT1 with its chaperone CD147 is involved in GISTs aggressiveness, pointing to a contribution of cancer cell metabolic adaptations in GIST development and/or progression.

**Keywords** Monocarboxylate transporters · CD147 · Cancer metabolism · GISTs

## Background

The estimated incidence of gastrointestinal stromal tumors (GISTs) ranges from 10 to 20 cases per million annually and the estimated prevalence is around 129 per million (Stamatikos et al. 2009). The majority of GISTs are found in the stomach (50–60%), followed by the small intestine (30–40%), colon and rectum (5–10%) and, rarely, in the esophagus (5%). GISTs are usually solitary tumors that mainly affect individuals over 50 years of age (Chourmouzi et al. 2009) and are generally composed of spindle cells, although sometimes they can display epithelioid features or a mixed pattern (Zhang et al. 2010; Miettinen et al. 2005). These tumors are characterized by a strong, diffuse staining for CD34 (60–70%) and CD117 (>95% of cases) (Blackstein et al. 2006), the latter encoded by the proto-oncogene *KIT* (Mushtaq et al. 2009).

GIST development is associated with activating mutations in the *KIT* gene (85–90%) and, less commonly (around 5%), in *PDGFRA* (Gomes et al. 2008; Martinho et al. 2009), which also encodes a type III tyrosine-kinase receptor. Approximately 10–15% of cases lack mutations in both *KIT* and *PDGFRA* (thus termed wild-type GIST) (Agaimy et al. 2009), and a subset of these wild-type GISTs display activating mutations of the oncogene *BRAF* (Martinho et al. 2009; Agaimy et al. 2009). The mutation profile has an important impact on the response of GIST patients to imatinib, a small-molecule inhibitor of tyrosine kinase. Importantly, patients with *KIT* exon 11 mutations have a better response rate to imatinib and longer overall survival and disease-free interval than patients with exon 9 mutations or wild-type *KIT* (Badalamenti et al. 2007). Nevertheless, it has been reported that patients on imatinib treatment can gain secondary *KIT* mutations, which cause insensitivity to the inhibitor. Resistance to these kinase inhibitors is

generally associated with distinctive clinical and molecular features (Gramza et al. 2009).

It was recently proposed that metabolic response measured by fluorodeoxyglucose positron emission tomography (FDG-PET) may be a useful early predictor of GIST response to treatment since there is a lower glucose uptake activity in imatinib-responsive GISTs, while imatinib-resistant GISTs show high glucose uptake capacity (Demetri et al. 2002; Cullinane et al. 2005; Holdsworth et al. 2007). In fact, the high metabolic activity related to intense glycolysis observed in sarcomas decreases and is related to clinical benefit, weeks or months before objective response based on tumor size (Demetri et al. 2002).

It is currently well established that most cancer cells, including GISTs, continually sustain high rates of glycolysis, thus generating high quantities of acids, especially lactic acid. Consequently, the pH of tumor-associated stroma is low, while the intracellular pH is either normal or higher than that of normal tissues. This calls for a transport mechanism capable of transferring acids from cancer cells to the external microenvironment (Chiche et al. 2010). The principal players known to participate in this acid transportation are members of the monocarboxylate transporter (MCT) family, which have a crucial role in conveying lactate across the plasma membrane, thus constituting attractive therapeutic targets (Kennedy and Dewhirst 2010). There is evidence that upregulation of MCTs occurs in many tumors, such as colorectal carcinomas (Pinheiro et al. 2008a), breast cancer (Pinheiro et al. 2010) uterine cervix (Pinheiro et al. 2008b) and lung cancer (Koukourakis et al. 2007), among others. There is also an association between lactate derived from tumor cells and cancer progression (Walenta & Mueller-Klieser 2004).

Hitherto, there are no data in the literature regarding the significance of MCT expression in GISTs. Given the aggressiveness of this type of tumor and the potential of MCTs as therapeutic targets, we sought to investigate the expression of MCTs and its chaperone CD147 (EMMPRIN) in a series of molecularly characterized GISTs.

## Methods

This study included samples from 51 patients consecutively examined and treated for gastrointestinal stromal tumors (GISTs) at Barretos Cancer Hospital, São Paulo, Brazil, between 2000 and 2008, and 13 patients from Garcia de Orta Hospital, Almada, Portugal, examined and treated between 1994 and 2003. Clinical-pathological data were retrospectively obtained from the files of the hospital medical records. Cases with a history of any previous cancer treatment were excluded. Tumors were classified in accordance with the WHO criteria and the parameters analyzed

included: age, gender, ethnicity, primary tumor site, tumor size, mitotic index, tumor necrosis and risk group as defined by Fletcher and collaborators (Fletcher et al. 2002). Other information included details on ascites metastases, disease recurrence, tumor persistence, distant metastases and cause of death when death occurred. Disease recurrence was defined as tumor detection at a clinical follow-up after 3 months that were free from disease. Tumor persistence was defined as the presence of a palpable tumor seen in clinical follow-ups within the first 3 months. Follow-up data were available for the majority of the patients and were collected through direct interviews with patients or their relatives, and by reviewing the in-hospital patient files. Additionally, information on GISTs molecular status (*KIT*, *PDGFRA* and *BRAF* gene mutations) was also available for patients from Barretos Cancer Hospital (de Oliveira et al. 2011), and performed in the remaining cases (Garcia de Orta Hospital) as previously described by our group (Gomes et al. 2008; Martinho et al. 2009; de Oliveira et al. 2011).

### MCT and CD147 immunohistochemistry

#### MCT detection

Immunohistochemistry was performed in accordance with the avidin-biotin-peroxidase complex principle (R.T.U. VECTASTAIN Elite ABC Kit (Universal), Vector Laboratories, Burlingame, CA, USA), with the primary antibodies for MCT1 (AB3538P, Chemicon International, Temecula, CA, USA), MCT2 (sc-14926, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and MCT4 (AB3316P, Chemicon International, Temecula, CA, USA), all diluted 1:200, as previously described by our group (Pinheiro et al. 2008a).

#### CD147 detection

Immunohistochemistry was performed using a streptavidin-biotin-peroxidase complex detection system (Ultravision Detection System Anti-polyvalent, HRP, Lab Vision Corporation, Fremont, CA, USA), using a primary antibody raised against CD147 (18-7344, ZYMED Laboratories Inc., South San Francisco, CA, USA), diluted 1:750, as previously described by our group (Pinheiro et al. 2009a).

#### Immunohistochemical evaluation

MCTs and CD147 immunoreactions were evaluated semiquantitatively using the criteria previously described (Pinheiro et al. 2008a). The immunoreaction extent was scored semiquantitatively as follows: 0: 0% presence of immunoreactive cells; 1: <5% presence of immunoreactive cells; 2: 5–50% presence of immunoreactive cells; and

3: >50% presence of immunoreactive cells. In addition, the intensity of staining was scored semiquantitatively as 0: negative; 1: weak; 2: intermediate; and 3: strong. The final immunoreaction score was defined as the sum of both parameters (extent and intensity), and grouped as negative (score 0 and 1) or positive (3–6). Immunohistochemistry evaluation was performed blindly by two independent observers (AL, CS). Discordant results were discussed under a double-head microscope and a final score was agreed. The presence of plasma membrane staining was not taken into consideration, since the morphology of GIST cells may mislead the interpretation.

### Statistical analysis

The available clinical-pathological and immunohistochemical data were analyzed using the SPSS software for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA). All comparisons were examined for statistical significance using Pearson's chi-square ( $\chi^2$ ) test or Fisher's exact test, as appropriate, with threshold for significance  $p$  values <0.05. Overall survival curves were plotted using the method of Kaplan-Meier and data were compared by means of the log-rank test. Cases lacking one or more of the clinic-pathological variables were not included in the specific analysis.


### Results

A total of 64 samples of GISTs, organized into Tissue Microarrays (TMA) were assessed for MCT1, MCT2, MCT4 and CD147 immunohistochemical expression.

Although MCT and CD147 expression have been described mainly in cell plasma membranes, we found that the expression of these proteins in GISTs is only visualized in the cytoplasm (Fig. 1). Importantly, the majority of positive cases showed both extensive and strong expression of these markers, especially for MCT2 (Fig. 1b). Overall, 89.1% (57/64) of the GISTs were positive for MCT1 (Fig. 1a), 90.3% (56/62) were positive for MCT4 (Fig. 1c), while CD147-positive reactions (Fig. 1d) were observed in 59.4% (38/64) of the cases. All cases were positive for MCT2 (64/64), therefore no additional statistics were performed for MCT2 expression. No associations between the expression of MCT1 and MCT4 and the chaperone CD147 were found (data not shown).

Regarding the molecular profile of the cases (Table 1), we found that CD147 was significantly more frequently expressed in *KIT*-mutated cases, as compared to *PDGFRA*-mutated or wild type cases ( $p=0.039$ ). However, no difference in mutation location was detected. No differences were

**Fig. 1** Immunohistochemical expression of monocarboxylate transporters (MCTs) and CD147 in gastrointestinal stromal tumors (GISTs). MCT1 (a), MCT2 (b) and MCT4 (c) were strongly and extensively observed in the cytoplasm of GIST cells while CD147 (d) presented a more focal expression



observed between the genetic status of the cases and expression of MCTs.

Concerning the clinical-pathological data (Table 2), we observed that tumors with absence of necrosis showed higher likelihood of being positive for MCT1, than did those presenting necrosis ( $p=0.042$ ). Additionally, all patients without locoregional relapse were positive for MCT4, while only 62.5% (5/8) cases with locoregional relapse presented MCT4 positive expression ( $p=0.014$ ). Importantly, CD147 expression was associated with a progressive increase in

Fletcher's Risk of Malignancy ( $p=0.020$ ). Co-expression of MCT1 or MCT4 with CD147 did not reveal any additional associations with the clinical-pathological data.

Overall survival analysis showed that patients had a median survival rate of 49 months, ranging from 1 to 180 months. Although no associations were observed for each protein individually, we found that patients with tumors co-expressing MCT1 and CD147 have a lower overall survival than the other group of patients (81 versus 158 months, respectively,  $p=0.037$ , Fig. 2).

**Table 1** Association between GIST molecular status and MCT and CD147 expression

	n	MCT1 positive (%)	<i>p</i>	MCT4 positive <sup>a</sup> (%)	<i>p</i>	CD147 positive (%)	<i>p</i>
Mutational status			0.528		0.298		0.039
<i>KIT</i> mutated	44	38 (86.4)		38 (86.4)		30 (68.2)	
<i>PDGFRA</i> mutated	7	7 (100.0)		7 (100.0)		3 (42.9)	
<i>KIT/PDGFRA/BRAF</i> wild-type	10	9 (90.0)		8 (100.0)		3 (30.0)	
Mutation location			0.689		0.192		0.137
<i>KIT</i> exon 9	6	5 (83.3)		6 (100.0)		4 (66.7)	
<i>KIT</i> exon 11	37	32 (86.5)		32 (86.5)		26 (70.3)	
<i>KIT</i> exon 17	2	2 (100.0)		1 (50.0)		0 (0.0)	
<i>PDGFRA</i> exon 18	7	7 (100.0)		7 (100.0)		3 (42.9)	
Mutation Type			0.611		0.193		0.356
Insertion and deletion	24	21 (87.5)		19 (79.1)		15 (62.5)	
Substitution and duplication	21	20 (95.2)		20 (95.2)		16 (76.2)	

<sup>a</sup> 2 missing cases

**Table 2** Association between GIST clinical-pathological parameters and MCT and CD147 expression

	n	MCT1 positive (%)	<i>p</i>	MCT4 positive <sup>a</sup> (%)	<i>p</i>	CD147 positive (%)	<i>p</i>
Ascites			0.209		1.000		0.134
Absence	42	39 (92.9)		35 (87.5)		25 (59.5)	
Presence	9	7 (77.8)		8 (88.9)		8 (88.9)	
Fletcher Risk of Malignancy			0.643		0.204		0.020
Very Low/Low	14	12 (85.7)		11 (84.6)		4 (28.6)	
Moderate	19	16 (84.3)		19 (100.0)		11 (57.9)	
High	27	25 (92.6)		23 (85.2)		20 (74.1)	
Locoregional relapse <sup>b</sup>			0.583		0.014		0.689
Absence	23	20 (87.0)		22 (100.0)		14 (60.9)	
Presence	8	6 (75.0)		5 (62.5)		4 (50.0)	
Cancer Persistence			0.143		0.665		0.217
No	31	26 (83.9)		27 (90.0)		18 (58.1)	
Yes	20	20 (100.0)		16 (84.2)		15 (75.0)	
Metastasis			1.000		0.077		0.603
Absence	28	25 (98.3)		26 (96.3)		19 (67.9)	
Presence	23	21 (91.3)		17 (77.3)		14 (60.9)	
Tumor size (cm)			1.000		0.325		0.164
≤10	41	36 (87.8)		37 (94.9)		21 (51.2)	
>10	20	18 (90.0)		17 (85.0)		14 (70.0)	
Mitotic index <sup>c</sup>			0.319		1.000		0.538
≤5	43	38 (88.4)		38 (90.5)		26 (60.5)	
>5	14	14 (100.0)		13 (92.9)		10 (71.4)	
Necrosis			0.042		1.000		0.740
Absence	40	38 (95.0)		35 (89.7)		23 (57.5)	
Presence	21	16 (76.2)		18 (90.0)		13 (61.9)	


<sup>a</sup> 2 missing cases<sup>b</sup> cases with no persistent disease were also analyzed<sup>c</sup> per 50 fields of high magnification

## Discussion

Cancer research has been traditionally focused on the genetic and epigenetic alterations occurring in tumor development. More recently, greater attention has been given to other components, such as the microenvironment and tumor energetics, as demonstrated by the emergence of a “new” hallmark of cancer—reprogramming energy metabolism (Hanahan & Weinberg 2011), emphasizing the importance of a broader analysis of cancer features.

Cancer metabolism is also gaining relevance in GISTs management. Underlying this phenomenon is the evidence provided by the relationship of glucose uptake, as measured by FDG-PET, with detection of primary GISTs and disease recurrence, pathological risk category (Otomi et al. 2010), as well as patient response to imatinib treatment (Demetri et al. 2002; Cullinane et al. 2005; Holdsworth et al. 2007). In fact, FDG-PET is currently used to evaluate the efficacy of imatinib in GIST patients (Demetri et al. 2002) as well as in preclinical

and clinical studies with new inhibitors for GISTs treatment (Pantaleo et al. 2010; Revheim et al. 2010). In chronic myelogenous leukemia (CML), imatinib-sensitive cells showed a decrease in both glucose uptake and lactate production as well as an increase in oxidative metabolism after imatinib treatment, while imatinib-resistant cells maintained the high levels of glucose uptake and lactate production characteristic of CML cells (Kominsky et al. 2009). Accordingly, in an in vivo model based on activating *KIT* mutations in GISTs, a decrease in glucose uptake, measured by FDG-PET, along with a decrease in the glucose transporter GLUT1 expression was observed after imatinib treatment in imatinib-responsive tumors. Therefore, imatinib may also act as a metabolic modulator, by depriving transformed cells from their key substrate, thus contributing to its cytotoxicity (Cullinane et al. 2005). Thus, GISTs with higher glycolytic rates may benefit more from imatinib treatment as well as other kinase inhibitors. As a result, metabolic characterization of GISTs prior and soon after treatment, may have predictive value and be used as an



**Fig. 2** Overall survival curve regarding MCT1 and CD147 co-expression in GIST patients. Patients with positive tumors for MCT1 and CD147 co-expression show shorter disease-free survival (*green line*) than patients without MCT1 and CD147 co-expression (*blue line*) ( $p=0.037$ )

early indicator of response. In this context, MCTs arise as relevant proteins involved in cancer metabolism that should be included in the metabolic characterization of tumors, as lactate transporters and pH regulators.

In the present study, we intended to address this issue in a series of molecularly (*KIT*, *PDGFRA* and *BRAF*) well characterized GISTs. We report expression of both MCT1 and MCT4 in around 90% of GISTs, which is in accordance with the high glycolytic metabolism characteristic of this type of tumors.

Evidence for the association between genetic background and tumor metabolism has been appearing in the last few years. It was recently described that in colorectal cancer cell lines, *GLUT1* was consistently up-regulated in cells with *KRAS* or *BRAF* mutations. Conversely, glucose-deprived colorectal cancer cells acquired *KRAS* mutations not present in the parent cells (Yun et al. 2009). *BRAF* V600E mutation was also shown to increase the expression of the metabolic regulator hypoxia-inducible factor-1 $\alpha$  (HIF- $\alpha$ ), at both mRNA and protein levels, in different cancer types including melanoma, colon and thyroid cancer (Kumar et al. 2007; Zerilli et al. 2010; Kikuchi et al. 2009). In the present study, no associations were found between oncogene mutations and the expression of MCTs. However, we found CD147 to be more frequently expressed in *KIT* mutated cases as compared to *PDGFRA* mutated and wild type cases. To the best of our knowledge, this is the first study showing this

association and more studies are warranted to confirm and uncover the molecular events underlying the possible regulation of CD147 by mutated *KIT*.

MCT activity largely depends on the location within the cell. In the cancer context, MCT isoforms 1 and 4 should be expressed at the plasma membrane for proper efflux of the accumulating lactate resultant from the high glycolytic rates. However, in the present study, MCT or CD147 expression in the plasma membrane was not clear. In fact, GISTs did not display clear plasma membrane staining as usually observed in carcinomas, probably due to the different cell organization of sarcomas, when comparing to epithelial malignancies, which make positive plasma membrane reactions unclear under microscopic observation.

Although plasma membrane expression was not observed, some significant correlations were obtained with the clinical-pathological data. MCT1 expression was associated with absence of tumor necrosis. However, one should be careful when considering this association with tumor necrosis, since this was evaluated independently from the analysis of immunohistochemical expression of the proteins herein studied. Therefore, this association does not mean that MCT1 is more frequently present in areas without necrosis, which goes against a previous study in breast cancer, showing MCT1 expression in peri-necrotic areas (Pinheiro et al. 2011). Also, MCT4 was unexpectedly associated with less locoregional relapse. As MCT4 contributes to extracellular acidification and lactate accumulation, which in turn are associated with invasion and metastasis (Rofstad et al. 2006; Walenta et al. 2000; Brizel et al. 2001), an association of MCT4 with an increase in locoregional relapse was expected, and not the contrary. Additional studies are warranted to confirm the value of this association. Finally, in accordance to its widely described poor prognostic value, CD147 was associated with high Fletcher Risk of Malignancy.

Importantly, we showed that co-expression of MCT1 and its chaperone CD147 (EMMPRIN) is associated with poor patient survival. Although MCTs have been previously associated with poor prognosis (Pinheiro et al. 2010; Fang et al. 2006; Pinheiro et al. 2009b), this is the first study showing an association of MCT1 with lower survival, reinforcing its role in cancer development and/or aggressiveness, as a player in the metabolic adaptations involved in carcinogenesis and progression towards malignancy. This result has clinical relevance as it suggests that GISTs may benefit from novel therapeutic approaches targeting MCT1 and CD147 (Kennedy & Dewhirst 2010).

## Conclusions

This study represents the first characterization of MCT protein expression in GISTs. We show that MCTs are highly

expressed in GISTs and that CD147 expression is associated with high Fletcher Risk of Malignancy. Importantly, co-expression of MCT1 with CD147 is associated with lower patient survival. Further studies evaluating the association of MCT expression with other metabolic regulators, such as GLUT1, and assessing the expression of these metabolic markers before and after imatinib treatment, would be of great importance to further clarify the interdependence between imatinib treatment and metabolic response. Altogether, the results herein reported enhance the comprehension of particular aspects of the biological behavior of gastrointestinal stromal tumors (GISTs), namely MCTs, which are important contributors to the metabolic phenotype of cancer cells.

**Acknowledgements and Funding** This study was supported by CNPq – Conselho Nacional de Desenvolvimento Científico e Tecnológico (Grant number: 476936/2008-0). CP and OM received fellowships from the Portuguese Science and Technology Foundation (ref. SFRH/BPD/69479/2010 and SFRH/BD/36463/2007, respectively).

**Conflict of interest statement** None declared.

**Authors' contributions** FB, RMR, ATO and AL were responsible for the study concept and design. CP, ATO, FB and RMR were responsible for study supervision, manuscript drafting and critical revision. MJB, CS, ALC, DM, TBS and VLV were responsible for clinical pathological collection. CP, ATO, OM, CS, SSS and TBS performed the immunohistochemical reactions, data analysis and interpretation and participated in the drafting of the manuscript. CS and AL evaluated the immunohistochemical reactions. All the authors read and approved the final manuscript.

## References

- Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFR $\alpha$  wild-type gastrointestinal stromal tumours. *J Clin Pathol* 62:613–616
- Badalamenti G, Rodolico V, Fulfaro F, Cascio S, Cipolla C, Cicero G, Incorvaia L, Sanfilippo M, Intrivici C, Sandonato L, Pantuso G, Latteri MA, Gebbia N, Russo A (2007) Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. *Ann Oncol* 18(Suppl 6):vi136–vi140
- Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulieres D, Swallow CJ, Verma S (2006) Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. *Can J Gastroenterol* 20:157–163
- Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhurst MW, Mueller-Klieser W (2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 51:349–353
- Chiche J, Brahimi-Horn MC, Pouyssegur J (2010) Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. *J Cell Mol Med* 14:771–794
- Chourmouzi D, Sinakos E, Papalavrentios L, Akriviadis E, Drevelegas A (2009) Gastrointestinal stromal tumors: a pictorial review. *J Gastrointest Liver Dis* 18:379–383
- Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, Ashman LK, McArthur GA, Thomas DM (2005) An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. *Cancer Res* 65:9633–9636
- de Oliveira AT, Reis RM, Afonso J, Martinho O, Matos D, Carvalho AL, Vazquez VL, Silva TB, Scapulatempo C, Saad SS, Longatto-Filho A (2011) Lymphangiogenic VEGF-C and VEGFR-3 expression in genetically characterised gastrointestinal stromal tumours. *Histol Histopathol* 26:1499–1507
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 347:472–480
- Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML (2006) The H<sup>+</sup>-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. *Mol Pharmacol* 70:2108–2115
- Fletcher JA, Fletcher CD, Rubin BP, Ashman LK, Corless CL, Heinrich MC (2002) KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized? *Am J Pathol* 161:737–738
- Gomes AL, Gouveia A, Capelinha AF, de la Cruz D, Silva P, Reis RM, Pimenta A, Lopes JM (2008) Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series. *J Clin Pathol* 61:203–208
- Gramza AW, Corless CL, Heinrich MC (2009) Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. *Clin Cancer Res* 15:7510–7518
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144:646–674
- Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD (2007) CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. *AJR Am J Roentgenol* 189:W324–W330
- Kennedy KM, Dewhurst MW (2010) Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. *Future Oncol* 6:127–148
- Kikuchi H, Pino MS, Zeng M, Shirasawa S, Chung DC (2009) Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1 $\alpha$  and -2 $\alpha$  in colon cancer. *Cancer Res* 69:8499–8506
- Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ (2009) Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. *Clin Cancer Res* 15:3442–3450
- Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E (2007) Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. *Cancer Biol Ther* 6:1476–1479
- Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X (2007) Mutant V600E BRAF increases hypoxia inducible factor-1 $\alpha$  expression in melanoma. *Cancer Res* 67:3177–3184
- Martinho O, Gouveia A, Viana-Pereira M, Silva P, Pimenta A, Reis RM, Lopes JM (2009) Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. *Histopathology* 55:53–62
- Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol* 29:52–68
- Mushtaq S, Mamoon N, Hassan U, Iqbal M, Khadim MT, Sarfraz T (2009) Gastrointestinal stromal tumors—a morphological and immunohistochemical study. *J Gastrointest Cancer* 40:109–114

- Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, Nishitani H (2010) Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. *J Med Invest* 57:270–274
- Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di BM, Castellucci P, Fanti S, Lollini PL, Bellan E, Castelli M, Rubello D, Biasco G (2010) Preclinical evaluation of KIT/PDGFR $\alpha$  and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. *J Exp Clin Cancer Res* 29:173
- Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F (2008a) Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. *Virchows Arch* 452:139–146
- Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, Jube LF, Queiroz GS, Schmitt F, Baltazar F (2008b) Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. *Int J Gynecol Pathol* 27:568–574
- Pinheiro C, Longatto A, Pereira SMM, Etlinger D, Moreira MAR, Jube LF, Queiroz GS, Schmitt F, Baltazar F (2009a) Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. *Disease Markers* 26:97–103
- Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, Zilberstein B, Ceconello I, Alves VA, Schmitt F, Baltazar F (2009b) The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. *Eur J Cancer* 45:2418–2424
- Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F (2011) GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. *Histol Histopathol* 26:1279–1286
- Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F (2010) Monocarboxylate transporter 1 is upregulated in basal-like breast carcinoma. *Histopathology* 56:860–867
- Revheim ME, Roe K, Bruland OS, Bach-Gansmo T, Skretting A, Seierstad T (2010) Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. *Mol Imaging Biol*
- Rofstad EK, Mathiesen B, Kindem K, Galappathi K (2006) Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. *Cancer Res* 66:6699–6707
- Stamatakis M, Douzinas E, Stefanaki C, Safioleas P, Polyzou E, Levidou G, Safioleas M (2009) Gastrointestinal stromal tumor. *World J Surg Oncol* 7:61
- Walenta S, Mueller-Klieser WF (2004) Lactate: mirror and motor of tumor malignancy. *Semin Radiat Oncol* 14:267–274
- Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W (2000) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. *Cancer Res* 60:916–921
- Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. *Science* 325:1555–1559
- Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V (2010) BRAF(V600E) mutation influences hypoxia-inducible factor-1 $\alpha$  expression levels in papillary thyroid cancer. *Mod Pathol* 23:1052–1060
- Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA (2010) Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. *Am J Surg Pathol* 34:53–64